Moshe Szyf

Oct 29, 2024 | nature.com | Moshe Szyf

Feb 6, 2024 | cellandgene.com | Moshe Szyf |Ahmed Abouzeid |Carol Houts |David Menahem

As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing. Additional critical raw materials also have batch-to-batch variability, which means the entire production process is a constant balancing act of adjusting the manufacturing process to create standardized manufacturing. Join Cell & Gene Live for a discussion on practical ways to overcome the challenges associated with batch-to-batch variation.

Jan 18, 2024 | cellandgene.com | Moshe Szyf

By Moshe Szyf, Ph.D., founder, HKG Epitherapeutics Ltd. Type 2 diabetes is a prevalent condition that disrupts the body's glucose processing. Approximately 10.4 percent of the U.S. population, comprising around 34 million Americans, grapple with this disease.1 Numerous factors elevate the risk of developing type 2 diabetes, including being overweight, having a family history of diabetes, high blood pressure, and smoking.